euro adhoc: Marseille-Kliniken AG / Financial Figures/Balance Sheet / - Turnover increase in first half-year 2008/2009 to EUR 116.8 million - Both segments generating positive contributions to incom

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

6-month report

10.02.2009

Berlin, 10 February 2009. Marseille-Kliniken AG was able to continue
to increase operating turnover in the first half of the current
financial year (1 July 2008 - 31 December 2008) by 4.2 % to EUR 116.8
million (previous year: EUR 112.1 million). As expected Group net
income after minority interest fell from EUR 12.1 million to EUR 1.0
million as a result of one-time effects (EUR 11.9 million) incurred
in the previous year. This translates into earnings per share of EUR
0.08 compared to EUR 1.00 in the previous year. EBIT/IFRS amounted to
EUR 4.2 million as planned after EUR 12.5 million including one-time
effects in the previous year. EBITDAR/IFRS reached EUR 31.7 million,
previously EUR 37.0 million. Equity amounted to EUR 80.8 million
after EUR 84.5 million in the previous year. The equity ratio
increased to 35.5 % (previous year: 33.8 %), while net debt dropped
slightly from EUR 66.4 million to EUR 65.9 million.

The drop in results according to German Commercial Code can be mainly
attributed to an extraordinary gain in the previous year, which back
then consisted of EUR 4.9 million from the corporation tax reform
2008 as well as EUR 8.1 million from the sale of a real estate asset.
These and similar one-time effects were not recorded in the period
under review.

Adjusted earnings according to DVFA/SG (IFRS) reached EUR 6.6 million
in the previous period and dropped slightly in the period under
review to EUR 6.2 million. Per share this amounts to EUR 0.51
(previous year: EUR 0.54). This was mainly attributable to increased
costs for securing heating oil prices, higher expenses for personnel
recruitment as well as audit costs. Adjusted EBITDAR increased from
EUR 31.5 million in the previous year to EUR 32.7 million, while
adjusted EBIT came in at EUR 9.0 million in the period under review
after EUR 10.0 in the previous year. At group level occupancy
continued at high levels, with capacity being increased by 200 beds.
Occupancy for the 9,100 beds reached 92.4 % (previous year: 92.5 % at
8,899 beds). Adjustments are mainly due to start up expenses for
seven Care facilities with currently 781 beds (8.6 % of capacity) as
well as four facilities, which are not yet operational, and a medical
centre in the Rehabilitation segment only taken over in mid 2008.

Capacity in the Care segment increased from 7,616 beds to 7,771 beds
in the period under review. Turnover in the segments increased from
EUR 86.8 million in the previous year to EUR 90.5 million. Earnings
according to DVFA/SG (IFRS) reached EUR 5.1 million (previous year:
EUR 6.6 million) were negatively impacted by expenses for securing
heating oil prices, personnel recruitment costs and audit costs.
Including the Düsseldorf and Potsdam facilities occupancy in Care
came in at 92.7 % after 93.6 % in the previous year.

The segment Rehabilitation developed very positively. In the period
under review its capacity increased slightly to 1,329 beds (previous
year: 1,283 beds) on the back of commissioning more beds in
Schömberg. Turnover generated increased from EUR 25.4 million in the
previous year to EUR 26.3 million. Earnings according to DVFA/SG
(IFRS) improved to EUR 1.1 million after previously breaking-even.
Restructuring measures continue to be successful and occupancy at the
segment improved from 89.1 % to 92.5 %.

As a result, Marseille-Kliniken AG continues to be heading towards
the set targets. The company is on a sound track which is almost
untouched by the currently difficult economic situation. This will
allow further sustained growth and at the same time means that the
company can make reliable plans for the development of its business.
We are expecting to see improvements in occupancy levels in Care,
while Rehabilitation will sustain its high occupancy levels. In Q3
Marseille-Kliniken will continue to benefit from falling start-up
expenses, which will have a positive impact on future quarterly
results. Tapping cost-saving potential in the current financial year
is to bring about a further improvement in profitability. Against
this backdrop, the Management Board is maintaining its growth
forecast of a 6.5 % average for the current and the next financial
year as well as EBIT return of at least 7 % for the current financial
year.

For more detailed information, please visit the website
www.marseille-kliniken.com to read the half-year report.

End of ad hoc release

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marseille-Kliniken AG

Axel Hölzer

CEO

Alte Jakobstraße 79/80

10709 Berlin

Germany

Tel.: +49 30 / 246 32-400

Fax: +49 30 / 246 32-401

www.marseille-kliniken.com

Hillermann Consulting

Christian Hillermann

Investor Relations for Marseille-Kliniken AG

Poststraße 14/16

20354 Hamburg

Germany

Tel.: +49 40 / 320 279 10

Fax: +49 40 / 320 279 114

www.hillermann-consulting.de

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / regulated dealing